目的 对比分析无关供者(unrelated donor,URD)与同胞相合供者(type matching sibling donor,MSD)异基因造血干细胞移植(allpgeneic hematopoietic stem cell transplantation,allo-HSCT)对急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)患儿的临床疗效.方法 选择2008年3月至2015年3月于本院行allo-HSCT治疗的ALL患儿58例为研究对象,根据供者来源将入选患儿分为URD组(24例)和MSD组(34例),比较两组患儿移植后造血重建情况、并发症发生率及随访生存情况.结果 两组患儿造血重建率、血小板重建时间、中性粒细胞重建时间、移植后相关并发症[急性移植物抗宿主病、慢性移植物抗宿主病、肺部感染、巨细胞病毒感染、出血性膀胱炎、EB病毒感染]发生率、总生存率及无病生存率比较均无显著差异(P>0.05).结论 URD allo-HSCT治疗儿童ALL的疗效与MSD allo-HSCT相当,可将其作为无同胞人类白细胞抗原匹配ALL患儿的治疗选择.
Objective To analyze the clinical efficacy of unrelated donor (URD) and type matching sibling donor (MSD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) for children with acute lymphoblastic leukemia (ALL). Method From March 2008 to March 2015, 58 cases of children with ALL treated by allo-HSCT in our hospital were selected as the research objects, according to the donors, they were divided into URD group (24 cases) and MSD group (34 cases). The hematopoietic reconst-itution, incidence of complications and follow-up survival were compared between the two groups after transplantation. Result There were no significant differences in the hematopoietic reconstitution rate, platelet reconstruction time, neutrophil reconstruction time, graft versus host disease (GVHD) the incidence of complications after transplantation [aGVHD, cGVHD, pulmonary infection, cytomegalovirus infection, hemorrhagic cystitis and EB virus infection] incidence, the total survival rate (OS) and disease-free survival (DFS) between the two groups (P>0.05). Conclusion The curative effect of URD allo-HSCT on ALL children is similar to that of MSD allo-HSCT, so it can be used as a treatment option for children without sibling HLA matching ALL.